Promising New CAR-T Therapy Shows Efficacy Against Solid Tumors, But Side Effects remain a Concern
Table of Contents
A groundbreaking study published in The Lancet offers renewed hope in the fight against solid tumors, demonstrating the effectiveness of a novel CAR-T cell therapy – satricabtagene autoleucel (satri-cel) – against gastric and gastroesophageal junction cancers. However, researchers caution that significant side effects require careful management.
The field of oncology has seen remarkable advancements, especially with CAR-T therapies for blood cancers.Unlike blood cancers, solid tumors present a complex and often impenetrable barrier to these engineered immune cells, likened by some to navigating a treacherous jungle. Since 2012, when Carl June administered the first CAR-T therapy to a young leukemia patient, the field has seen remarkable progress, with approvals beginning in Italy in 2019 and now six CAR-Ts available in Europe. But extending this success to solid tumors has proven elusive.
Targeting Claudin 18.2: A New Approach
Developed by CARsgen Therapeutic, satri-cel represents a targeted approach to overcoming these challenges.The therapy utilizes a patient’s own T cells – an “autologous” therapy – genetically modified to express a chimeric antigen receptor (CAR) designed to recognize claudin 18.2 (CLDN18.2). This molecule is highly expressed in certain gastrointestinal tumors, making it an attractive target. Researchers employed a lentiviral vector to modify the T lymphocytes, equipping them with an intracellular signaling domain that enhances their activation and persistence within the body.
“Claudin 18 is known for its role in some gastric tumors and has been at the center of numerous clinical investigations,” highlighting its potential beyond just gastric cancer, including pancreatic cancer. studies from the University of Verona and the Veneto Oncology Institute (IOV) have shown a correlation between claudin 18 expression and the presence of T lymphocytes in various tumor types, suggesting a link to a more favorable prognosis.
Phase II Trial Results: Significant Improvement in Progression-Free Survival
The Phase II clinical trial, presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago, involved 156 patients with advanced gastric or gastroesophageal junction cancer who had previously undergone at least two unsuccessful treatments. Patients were divided into two groups: 104 received satri-cel, while 52 received standard care consisting of drugs like nivolumab, paclitaxel, and rivoceranib.
The results were compelling. A remarkable 35% of patients treated with satri-cel responded to therapy, compared to just 4% in the control group. Furthermore, the median progression-free survival (PFS) was significantly longer in the satri-cel group – 9.07 months versus 3.45 months for standard care.
A Critical Caveat: High Incidence of Severe Side Effects
Despite the encouraging efficacy data, the trial revealed a significant safety concern. A staggering 99% of patients receiving satri-cel experienced a grade 3 or higher adverse event, compared to 63% in the control group. The most common side effects included a severe drop in lymphocyte and white blood cell counts, and a high incidence of cytokine release syndrome (CRS) – a systemic inflammatory response triggered by the activated CAR-T cells – affecting 95% of treated patients.
While the medical team is becoming increasingly adept at managing these responses, strict patient monitoring remains crucial.”The safety of the new experimental therapy is fundamental,” one analyst noted, “and the response of the immune system, even if aggressive, is considered an almost ‘obvious’ event.” Further research is needed to refine the therapy and identify patients most likely to benefit while minimizing the risk of severe side effects.
The growth of satri-cel represents a significant step forward in the challenging quest to harness the power of CAR-T therapy against solid tumors. While the path forward requires careful attention to safety and further investigation, this study offers a beacon of hope for patients battling advanced gastric and gastroesophageal junction cancers.
- Three Wyoming Residents Pedaling in Annual Pan-Event to Fight Cancer (news-usa.today)
